Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US
Shots:
- Nanobiotix launches a new subsidiary- Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability- toxicity- and efficacy in the healthcare system in France & the US
- Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received marketing approval in Europe
- Curadigm technology increases the efficacy at current doses- decreases toxicity & cost- allowing to utilize new approaches for drug designing and is presented at AACR 2019
Ref: GlobeNewsWire | Image: My French Startup
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com